Skip to main content

Peer Review reports

From: Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Original Submission
14 May 2014 Submitted Original manuscript
7 Jul 2014 Author responded Author comments - Barbara Burtness
Resubmission - Version 2
7 Jul 2014 Submitted Manuscript version 2
24 Jul 2014 Reviewed Reviewer Report - Sarah Damery
28 Aug 2014 Reviewed Reviewer Report - Mehmet Sen
3 Nov 2014 Author responded Author comments - Barbara Burtness
Resubmission - Version 3
3 Nov 2014 Submitted Manuscript version 3
Publishing
10 Nov 2014 Editorially accepted
29 Nov 2014 Article published 10.1186/1745-6215-15-469

You can find further information about peer review here.

Back to article page

Trials

ISSN: 1745-6215